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Introduction 
β-thalassemia, an inherited recessive condition, is caused by one or more of over 200 
mutations in the β-globin gene in man.  It occurs in all populations, however it is much 
more common in some populations, ranging from 10% down to others with 1% carriers 
[1].  Many countries now screen couples before marriage or during pregnancy to assess 
whether or not they are at risk of having a child with β-thalassemia major (the severe 
homozygous or compound heterozygous state) since these conditions have significant 
lifelong medical morbidity and limited life expectancy.  Although the precise 
characterization of the β-thalassemia mutation requires DNA analysis, the accurate 
measurement of HbA2 is the first level diagnostic parameter for the routine detection of 
most carriers of the common “High HbA2” type of β-thalassemia. Most service 
laboratories and clinicians have to make a provisional diagnostic decision depending on 
the HbA2 level.  As there might be only a small difference in the level of HbA2 between 
people who are carriers of High HbA2 β฀thalassemia and those who are not carriers, 
the performance of the HbA2 analysis must be accurate and should be interpreted in 
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association with the red cell indices. The red cell hematology should be that of a chronic 
microcytic state with moderate erythrocytosis relative to the hemoglobin concentration 
(unless folate deficient) and not responding to appropriate iron therapy.  Although 
“HbA2 levels above 3.5% are considered the standard cut off value, above which 
heterozygosity for β-thalassaemia is indicated” [2] a HbA2 of 4% is usually considered 
a safe threshold to diagnose β-thalassemia trait with most carriers having levels of 3.8% 
or above; levels below 3.0% are usually considered safe to exclude cases of the 
common High HbA2 β-thalassemia trait if normocytic and normochromic as most 
people who are not carriers have a HbA2 less than 3.2%.   However, even with greater 
accuracy and less imprecision the use of HbA2 testing alone will not be able to exclude 
cases of borderline or “Normal HbA2” β-thalassemia or combinations of β and δ-
thalassemia where a microcytic, hypochromic anemia with a normal HbA2 might be 
mistaken for α-thalassemia.  Because of this, individuals with suspicious red cell 
indices and normal ferritin and/or iron or zinc protoporphyrin levels deserve further 
evaluation.  However, greater accuracy and less imprecision in the HbA2 assay will both 
decrease needless testing from false positives and improve the detection of borderline 
cases.  The level of the HbA2 fraction may be measured as elevated in some non-β-
thalassemic circumstances or may be elevated due to technical artifacts [3].  For these 
reasons the HbA2 accuracy is especially important in the critical area between 3.0 and 
4.0% and the imprecision should be such that an SD of 0.05 (or CV, or RSD, of 2%) 
can be obtained (duplicates within 0.2% in the final numeric result).  Unfortunately it is 
not possible to definitively diagnose or exclude a carrier state with a HbA2 between 3.0 
and 4.0% without further investigation.  As stated previously [3] it is important to both 
detect and quantitate any HbA2 variant that is present (due to either an α or δ globin 
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chain mutation) and include it in the total HbA2 reported.  If this is not done, people 
who also carry β-thalassaemia, may be missed.  
The International Committee for Standardization in Haematology (ICSH) published 
recommended manual methods of measuring HbA2 in 1978 [4] and discussed the 
various automated approaches in 2012 [3].  The ICSH Board have decided that since the 
various models of High Performance Liquid Chromatography (HPLC) and Capillary 
Electrophoresis (CE) equipment available from different manufacturers have been 
shown to give different values of HbA2 in quality assessment schemes [5, 6], it would 
be useful to discuss how such equipment should be assessed by manufacturers of each 
system, as well as by service laboratories (especially before purchasing equipment), 
many of which do not have ready access to DNA analysis.  Ideally, reliable HbA2 
standard materials should be available that are physically and biochemically identical to 
clinical samples analyzed by dedicated HPLC and CE devices and with the HbA2 values 
obtained from electrophoretic separation on cellulose acetate membranes with elution 
and spectrophotometric measurement of native fractions [4] [7].  These standards could 
then be used by manufacturers in order to have a unique and reliable calibration with 
low, normal and elevated values. Automatic measurement of HbA2 and hematological 
parameters should then be sufficiently accurate to provisionally diagnose, or exclude the 
carrier state of the common ‘High HbA2’ β-thalassemia trait and should be at least as 
good as the manual but laborious methods used by experienced technologists.฀  In 
complex situations such as in the presence of iron depletion, alpha thalassemia or 
‘Normal HbA2’ β-thalassemia, or δ-thalassemia which decrease the elevated HbA2 level 
in β-thalassemia carriers, accurate diagnostic conclusions cannot be drawn without 
additional (DNA) analysis. 
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Aspects of analytical performance such as peak shape and especially tailing; integration 
mode, separation and baseline, technical accuracy, linearity, precision, carry-over and 
calibration of new columns and buffer, especially pH, batches need to be assessed by 
the technologist, to ensure that the instrument will be able to perform well and to fulfil 
the clinical need after installation and set up according to the instructions of the 
manufacturer [8].  It is also important that the total peak area is within that 
recommended by the manufacturer of the equipment otherwise the quantitation may be 
incorrect.  In case of doubt, performance can be controlled by using samples of known 
value that should be certified by a National or an International body such as the World 
Health Organization (WHO) or donated in-house HbA2 samples validated by a 
reference laboratory or by using remnant blood samples from previously measured fresh 
clinical samples.  At the present time, (2015) the only international recognized reference 
material for HbA2 is the WHO International Reference Reagent which has an assigned 
value of 5.3 ± 0.066% obtained by an international collaborative study using 
electrophoresis and elution, micro-column chromatography and HPLC.  This is held by 
the UK National Institute for Biological Standards and Control (NIBSC) in Blanche 
Lane, South Mimms, Potters Bar, Herts, EN6 3QG; (www.nibsc.org).  Controls made 
from samples obtained from members of staff can be useful for laboratories that do not 
have access to commercial controls or the National/International standards.  Samples 
obtained by venesection of staff members will usually have stable HbA2 levels as long 
as iron deficiency does not occur.  For this reason blood donors and women of child 
bearing age should be avoided unless their blood count and iron status are confirmed as 
normal.  Such material can serve as suitable controls since the material will be similar to 
the other samples analyzed.  If this material can be validated by a reference laboratory, 
it can also be used as a secondary standard.  A ‘Reference Laboratory’ should have 
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access to the WHO Reference material (or another internationally accredited reference 
material) and have experience of, and use, the cellulose acetate electrophoresis and 
elution technique recommended by ICSH [4] since automated HPLC or CE systems 
should not be used to assign values to samples for standardization purposes.  The WHO 
material mentioned above has now been available for more than 25 years and is still 
stable, however the International Federation of Clinical Chemists (IFCC) is working on 
a new HbA2 certified reference material as a primary standard[9].  The ICSH and IFCC 
are planning to form a joint working party on this subject and with a view to produce 
secondary standards for use by laboratories and manufacturers.  When assessing 
automated commercial instruments for suitability to quantitate HbA2 in order to 
diagnose or exclude the diagnosis of β-thalassemia trait it is important to assess the 
accuracy and imprecision in the diagnostic range and in particular in the critical range 
between 2.8 and 4.2% of the total hemoglobin.  Within this critical range the 
imprecision should be ± 0.2% of the HbA2 in the final numerical result which is the 
current precision that can be obtained by an experienced technologist using the 
recommended manual (although time consuming) methods [4]. 
Assessment  [10] [11] [12] [13] As stated above, the technologist needs to assess 
separation and resolution (overlaps), peak shape (asymmetry), integration and baseline 
stability, carryover, accuracy, imprecision and linearity of the specific instrument used.  
The samples used for the following analyses must not contain any hemoglobin variant 
and the ‘blood’ diluent should contain no or very little HbA2 (see below).  Three 
replicates should be analyzed on at least three separate occasions on different days of 
the week. 
System suitability 
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It is essential that before performing the following validation steps the electro-
mechanical components of the equipment (HPLC or CE) are operating in accordance 
with the manufacturer’s instructions (e.g. for HPLC flow rates are correct and constant, 
for CE voltages and current are stable; detectors have been set at the correct 
wavelengths). Eluents and buffers should be as supplied by the system manufacturer; or 
made in the laboratory using good laboratory practices when the pH should be checked 
with a fully and properly calibrated pH meter.  Carryover may be minimised and 
resolution improved by regular cleaning of the sample lines as recommended by the 
instrument manufacturer.  The following are basically testing the column and capillary 
performance. 
Peak shape, separation and baseline  Analyze a blood sample that does not 
contain a variant hemoglobin and check that the chromatogram (or electropherogram) 
shows complete separation of the HbA and HbA2 peaks with return to baseline between 
them and that the peaks are symmetrical. 
Imprecision Measure one sample at least 3 times and then calculate the mean, range 
and SD.  This is the intra-day variation. Repeat the measurement of the same sample on 
3 occasions (inter-assay variation) and compare the mean, range and SD.  Between 
assays the sample should be kept at 4ºC.  
Carryover [14] [15] [16] Carryover can lead to erroneous peak quantitation and 
even spurious peaks leading to diagnostic errors.  It is therefore very important to know 
whether carryover occurs and if so what its clinical implications may be.  When 
quantitating HbA2 it is especially important to know if there is any carryover from HbE 
or HbC since they elute with, or close to, HbA2 and HbA2 variants respectively on 
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HPLC and the peaks are at least ten to twenty times larger than the HbA2 peak so that 
even a small degree of carryover can cause a clinically significant increase in the HbA2.  
If the HbA2 level is clinically important in a particular patient sample it is probably best 
to exclude any result that follows a sample containing HbE or HbC, or a variant 
hemoglobin that elutes in a similar position ,and rerun the sample. 
 
To assess the amount of HbA2 carryover that occurs requires two samples, one having a 
low or low normal HbA2 (aim for about 2%) labelled ‘L’ and another sample having a 
HbA2 considerable raised (aim for at least 5%) labelled ‘H’.  These samples should be 
analyzed in the following way.  Each sample should be analyzed three times in the 
following order:  L1, L2, L3, H1, H2, H3 which shows the carryover from a normal to a 
thalassemia trait sample followed by H1, H2, H3, L1, L2, L3 to show the carryover 
from a thalassemia trait sample to a normal sample.  The percentage carryover from the 
first group is calculated as follows: 
 
   H1-H3  x 100 %     and the second group:  L1-L3  x 100 % 
   L3-H2     H3-L2 
 
A clinical laboratory should repeat the sequence of twelve assays five times. A 
manufacturer should plan to repeat the sequence at least twenty times.  The mean 
carryover is then calculated for the two situations.  A similar approach can be used to 
calculate the carryover from HbE or HbC to HbA2.  The HbE or HbC sample should be 
at the highest level likely to be encountered in routine laboratory practice and will 
replace the ‘High’ raised HbA2 in the above example. 
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Carryover from the HbA2 should be less than a numeric 0.1% (equivalent to a carryover 
of 2% for a HbA2 of 5%).  Since even this proportion of HbE would lead to a very large 
error in the HbA2 of a following sample, no carry over should be accepted from any 
variant eluting in the HbA2 region. 
 
Accuracy Measure a reference material 3 times and also relate it to the linearity 
results. 
 
Linearity Since for clinical reasons HbA2 is measured as a percentage of the total 
hemoglobin, the reconstituted WHO reference material (or any other reference material) 
should be stored in the manner indicated by the reference organisation and should be 
diluted in blood containing very little or ideally no HbA2 (see below) and not in water 
or buffer.  Mix the reference material with the diluent in the proportions given in the 
table below and then analyse the mixture in duplicate on three occasions on different 
days of the week.  In a similar way, undertake the cellulose acetate electrophoresis 
analyses.  Plot the results against the theoretical value obtained by calculation (see table 
below).  Ideally use a blood sample from a donor with homozygous delta thalassemia 
for all dilutions, but since this may be difficult to obtain, umbilical cord blood 
(preferably from a premature baby) can be used since this will contain very little HbA2 
(usually less than 0.5%).  The same pipette and settings should be used for all pipetting 
to minimize any calibration error.  The hemoglobin concentration of donor blood 
sample should be similar (within 10%) to that of the WHO preparation (98 g/L) but the 
actual hemoglobin concentration of both should be measured using the same technique, 
since any difference in concentration will need to be taken into account to calculate the 
actual concentration of HbA2 in the mixture.   
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Integration Integration should employ a suitably fast data acquisition rate for HPLC 
see Meyer [17].  For CE a similar requirement applies to CE data systems but the 
relative areas must be calculated using ‘spacial areas’ (measured areas divided by the 
migration time). 
 
Table 1 near here 
Technique for linearity study 
 
1. Open one ampoule of the WHO Reference Material (or other Reference Material) 
and reconstitute by adding 0.5mL distilled water to the vial.  Mix well and when the 
lyophilised material has all dissolved it will produce 0.5ml of hemolysate at 
approximately 100g/L.  If a different reference material is used reconstitute it using 
the appropriate recommended method. 
 
2. Wash the red cells from 2ml ‘diluent’ blood three times with saline, centrifuge 
(1000g for 10 minutes) and remove the supernatant. Then haemolyse by adding an 
equal volume of water, mix and stand for 20 minutes, then freeze and thaw the red 
cells, then centrifuge (1000g for 10 minutes) to separate the red cell membranes, 
remove and keep the supernatant hemolysate.   
 
3. Measure the Hb concentration of both the reconstituted WHO (or other) Reference 
Material and the haemolysed cord blood using the same equipment and reagents and 
record the results.  Only use a very small volume of the reference material as most of 
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it will be needed for the linearity assessment. 
 
4. Using the same pipette, prepare 6 dilutions of the WHO (or other) reference material 
as given in the Table.  The same pipette should be used for all dilutions since this 
will reduce the effect of any inherent inaccuracies in the pipette calibration.  
 
5. Analyse the HbA2 in the undiluted WHO (or other) reference material & undiluted 
diluent blood and in the 6 dilutions from (4) above on the HPLC or CE equipment to 
be tested using the manufacturers directions for small (paediatric) samples.  Also 
analyse each dilution by the ICSH recommended cellulose acetate electrophoresis 
and elution method [4]. 
 
6. Use the results from (3) and (5) above as described below to plot the linearity.  
Linearity can be plotted as the dilution factor on the X-axis and the obtained HbA2 
percentage on the Y-axis.  The expected HbA2 percentage can also be plotted against 
the obtained HbA2 percentage in order to assess the degree of correlation. 
 
Interpretation of results 
Peak shape, separation and baseline:  When analyzing a sample that does not contain a 
variant hemoglobin, peaks should be Gaussian and symmetrical, with minimal and 
ideally no peak tailing [11].  The HbA2 peak should be completely separated from the 
HbA (on CE) or HbAo (on HPLC) peaks, with the nadir between the two peaks on the 
baseline.  The noise and drift of the baseline should be similar to that obtained when 
analyzing a buffer blank.  Manufacturers should aim to supply columns that in their 
system have an asymmetry factor (As) between 0.9 and 1.1 and a resolution (Rs) 
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between adjacent peaks of greater than 1.75.  These two factors are essential elements in 
assessing routine suitability of the separations obtained.  These are described in detail in 
most HPLC texts such as Meyer [17]. 
 
When using manual techniques such as electrophoresis and elution that were 
recommended in the ICSH 1978 publication, complete separation of HbA2 from HbA is 
possible, as is a relative standard deviation (similar to the CV) of 2.0%.  Similar 
performance should be obtained by automated equipment in order to provide adequate 
clinical diagnoses. 
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Table 1.  Suggested mixing proportions for linearity testing.  
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 * Ideally, the diluent should be a blood sample from a person with homozygous 
delta-thalassemia, but if this is not available a sample of umbilical cord blood 
(preferably from a premature infant) can be used as this will usually contain less than 
0.5% HbA2. 
 
 § The actual concentration of HbA2 in the diluted samples is calculated (see 
below) from the ratio of WHO (or other) Reference material to diluent adjusted for 
the difference in hemoglobin concentrations.  This calculation should not be used for 
the undiluted reference material or for the 100% diluent.  If umbilical cord blood is 
used as the diluent there is likely to be a small amount of HbA2 in the diluent and 
this is accounted for in the second part of the equation. 
WHO (or other) 
Reference Material volumes 
Diluent * 
volumes 
Approx HbA2 concentration 
(%)   § 
5 0 5.3 
4 1 4.2 
5 2 3.8 
4 2 3.5 
5 3 3.3 
4 3 3.0 
2 3 2.1 
0 5 0 
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HbA2 percentage in the mixture  = [A  x  B/(B+C)  x  D/E] + [F  x  C/(B+C)  x  E/D] 
 
 Where:  A  =  HbA2 percentage in the WHO (or other) reference material 
B  =  Volume of ‘Reference material’ 
C  =  Volume of ‘Diluent’ 
D  =  Hb concentration of ‘Reference material’ 
E  =  Hb concentration of ‘Diluent’ 
F  =  HbA2 percentage in the ‘Diluent’ 
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